Microbot Medical Successfully Completes An Extensive Pre-Clinical Study Performed In The U.S.
Portfolio Pulse from Happy Mohamed
Microbot Medical Inc. (NASDAQ:MBOT) has successfully completed an extended pre-clinical study of its LIBERTY® Robotic Surgical System in the U.S. The study, conducted by leading interventional radiologists, achieved a 100% success rate with no observable complications. The company received positive feedback regarding the system's intuitiveness, ease of use, and remote operation capabilities. This study is expected to assist in the future adoption of LIBERTY when commercialized.
June 29, 2023 | 12:37 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Microbot Medical's successful pre-clinical study of its LIBERTY Robotic Surgical System in the U.S. is a positive development for the company. The positive feedback and 100% success rate could boost investor confidence and potentially lead to an increase in the company's stock price in the short term.
The successful completion of the pre-clinical study indicates that the LIBERTY Robotic Surgical System is functioning as intended, which is a positive sign for investors. The positive feedback from the study participants further boosts the product's credibility, which could lead to increased investor confidence and a potential rise in the company's stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100